Statement on efforts to help make development of biosimilar and interchangeable insulin products more efficient

Source:
US Food and Drug Administration - FDA
Publisher:
US Food and Drug Administration
Publication date:
25 November 2019

Abstract

This draft guidance is intended to help guide efficient product development by clarifying what data and information may, or may not be needed to support a demonstration of biosimilarity or interchangeability for a proposed insulin product.